The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
Published version of a preprint
Abstract
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. On the basis of 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved overall response and disease control rates (23.9% and 55.3%) compared with previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients. These data demonstrate the benefit of molecular stratification in rare cancers and represent a resource that may promote clinical trial access and drug approvals in this underserved patient population. SIGNIFICANCE: Rare cancers are difficult to treat; in particular, molecular pathogenesis-oriented medical therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing enables molecularly informed treatments that lead to clinical benefit in a substantial proportion of patients with advanced rare cancers and paves the way for future clinical trials. See rela…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Perturbation-response genes reveal signaling footprints in cancer gene expression
(2017) · doi:10.1038/s41467-017-02391-6 · Cited by 1,108
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086
Alvarez, M. J., Shen, Y., Giorgi, F. M., Lachmann, A., Ding, B. B., Ye, B. H., & Califano, A. (2016) · Nature Genetics · doi:10.1038/ng.3593 · Cited by 966
Cited by
van Tilburg, C. M., Pfaff, E., Pajtler, K. W., Langenberg, K. P. S., Fiesel, P., Jones, B. C., Balasubramanian, G. P., Stark, S., Johann, P. D., Blattner-Johnson, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0094 · Cited by 262
Self-citationBig data in basic and translational cancer research
Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254
Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0538 · Cited by 206
“The use of each patient as his or her own control allows us to evaluate the individual benefit, and it became common in precision medicine trials, such as the WINTHER and MASTER trials including heterogenous cancer entities (29, 38).”
MethodMatsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“To select efficient drugs, recent clinical trials have focused on multi-omics profiling of patients with cancer by analyzing genome-wide data, including data from DNA sequencing, gene expression profiling, and copy number profiling [66].”
BackgroundSarcoma care in the era of precision medicine
Wallander, K., Öfverholm, I., Boye, K., Tsagkozis, P., Papakonstantinou, A., Lin, Y., & Haglund de Flon, F. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13717 · Cited by 30
Metadata
- Authors
- Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., Gieldon, L., Möhrmann, L., Hanf, D., Teleanu, V., Heilig, C. E., Lipka, D. B., Allgäuer, M., Ruhnke, L., Laßmann, A., Endris, V., Neumann, O., Penzel, R., Beck, K., Richter, D., Winter, U., Wolf, S., Pfütze, K., Geörg, C., Meißburger, B., Buchhalter, I., Augustin, M., Aulitzky, W. E., Hohenberger, P., Kroiss, M., Schirmacher, P., Schlenk, R. F., Keilholz, U., Klauschen, F., Folprecht, G., Bauer, S., Siveke, J. T., Brandts, C. H., Kindler, T., Boerries, M., Illert, A. L., von Bubnoff, N., Jost, P. J., Spiekermann, K., Bitzer, M., Schulze-Osthoff, K., von Kalle, C., Klink, B., Brors, B., Stenzinger, A., Schröck, E., Hübschmann, D., Weichert, W., Glimm, H., & Fröhling, S.
- Affiliations
- German Cancer Research Center (DE)
- University Hospital Carl Gustav Carus (DE)
- 1Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
- University Hospital Heidelberg (DE)
- Nuremberg Hospital (DE)
- Robert Bosch Hospital (DE)
- Heidelberg University (DE)
- University of Würzburg (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Essen University Hospital (DE)
- Goethe University Frankfurt (DE)
- Johannes Gutenberg University Mainz (DE)
- University of Freiburg (DE)
- Medical University of Graz (AT)
- Ludwig-Maximilians-Universität München (DE)
- Universitätsklinikum Tübingen (DE)
- 49DKTK, Tübingen, Germany.
- 51Clinical Study Center, Charité – Universitätsmedizin Berlin, and Berlin Institute of Health, Berlin, Germany.
- Luxembourg Institute of Health (LU)
- Technical University of Munich (DE)
- Corresponding author
- Glimm, Hanno
- Fröhling, Stefan
- ORCID
- Horak, Peter
- Heining, Christoph
- Kreutzfeldt, Simon
- Hutter, Barbara
- Mock, Andreas
- Hüllein, Jennifer
- Fröhlich, Martina
- Uhrig, Sebastian
- Jahn, Arne
- Rump, Andreas
- Gieldon, Laura
- Möhrmann, Lino
- Hanf, Dorothea
- Heilig, Christoph E.
- Lipka, Daniel B.
- Allgäuer, Michael
- Ruhnke, Leo
- Endris, Volker
- Neumann, Olaf
- Richter, Daniela
- Buchhalter, Ivo
- Augustin, Marinela
- Aulitzky, Walter E.
- Hohenberger, Peter
- Kroiss, Matthias
- Schirmacher, Peter
- Schlenk, Richard F.
- Keilholz, Ulrich
- Klauschen, Frederick
- Folprecht, Gunnar
- Bauer, Sebastian
- Siveke, Jens Thomas
- Brandts, Christian H.
- Kindler, Thomas
- Boerries, Melanie
- Illert, Anna L.
- von Bubnoff, Nikolas
- Jost, Philipp J.
- Spiekermann, Karsten
- Bitzer, Michael
- von Kalle, Christof
- Klink, Barbara
- Brors, Benedikt
- Stenzinger, Albrecht
- Schröck, Evelin
- Hübschmann, Daniel
- Weichert, Wilko
- Glimm, Hanno
- Fröhling, Stefan
- Venue
- Cancer Discovery
- Published
- 2021-06-10
- Volume
- 11
- Issue
- 11
- Pages
- 2780-2795
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3171689169
- Cited by
- 290
- References
- 51
- Citations by year
- 2026: 49 · 2025: 57 · 2024: 54 · 2023: 67 · 2022: 50 · 2021: 12
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- German Cancer Research Center (H021)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- rare tumor, molecular profiling, molecular tumor board, targeted therapy, biomarkers, molecular stratification, clinical decision-making, progression-free survival, clinical trial access, genetic counseling, advanced cancer
- MeSH terms
- Exome Sequencing, Adult, Humans, Neoplasms, Gene Expression Profiling, Genomics, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0126
- The paper
- Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., Gieldon, L., Möhrmann, L., Hanf, D., Teleanu, V., Heilig, C. E., Lipka, D. B., Allgäuer, M., Ruhnke, L., Laßmann, A., . . . Fröhling, S. (2021). Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.